מדינה: ארצות הברית
שפה: אנגלית
מקור: NLM (National Library of Medicine)
DOXAZOSIN MESYLATE (UNII: 86P6PQK0MU) (DOXAZOSIN - UNII:NW1291F1W8)
Bryant Ranch Prepack
DOXAZOSIN MESYLATE
DOXAZOSIN 2 mg
ORAL
PRESCRIPTION DRUG
Doxazosin tablets are indicated for the treatment of the signs and symptoms of BPH. Doxazosin tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerou
NDC: 71335-0002-1: 30 Tablets in a BOTTLE NDC: 71335-0002-2: 60 Tablets in a BOTTLE NDC: 71335-0002-3: 90 Tablets in a BOTTLE NDC: 71335-0002-4: 28 Tablets in a BOTTLE NDC: 71335-0002-5: 18 Tablets in a BOTTLE
Abbreviated New Drug Application
DOXAZOSIN- DOXAZOSIN TABLET BRYANT RANCH PREPACK ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE DOXAZOSIN TABLETS SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR DOXAZOSIN TABLETS. DOXAZOSIN TABLETS, FOR ORAL USE INITIAL U.S. APPROVAL: 1990 INDICATIONS AND USAGE Doxazosin tablets are an alpha adrenergic antagonist indicated for: (1) Signs and symptoms of Benign Prostatic Hyperplasia (BPH) Treatment of HypertensionTreatment of Hypertension DOSAGE AND ADMINISTRATION For the treatment of BPH: Initiate therapy at 1 mg once daily. Dose may be titrated at 1 to 2 week intervals, up to 8 mg once daily.(2.2) For the treatment hypertension: Initiate therapy at 1 mg once daily. Dose may be titrated as needed, up to 16 mg once daily. (2.3) DOSAGE FORMS AND STRENGTHS Tablets: 1 mg, 2 mg, 4 mg, 8 mg. CONTRAINDICATIONS Hypersensitivity to doxazosin, other quinazolines, or any other ingredient in doxazosin tablets. (4) WARNINGS AND PRECAUTIONS Postural hypotension with or without syncope may occur. (5.1) Risk of Intraoperative Floppy Iris Syndrome during cataract surgery. (5.2) Screen for the presence of prostate cancer prior to treatment for BPH and at regular intervals afterwards. (5.3) ADVERSE REACTIONS The most commonly reported adverse reactions from clinical trials are Fatigue, malaise, hypotension, and dizziness. (6.1) TO REPORT SUSPECTED ADVERSE REACTIONS, CONTACT APOTEX CORP AT 1-800-706-5575 OR FDA AT 1-800-FDA-1088 OR _WWW.FDA.GOV/MEDWATCH_. DRUG INTERACTIONS Strong cytochrome P450 (CYP) 3A inhibitors may increase exposure to doxazosin and increased risk of hypotension. (7.1) Concomitant administration of doxazosin tablets with a phosphodiesterase-5 (PDE-5) inhibitor can result in additive blood pressure lowering effects and symptomatic hypotension. (7.2) USE IN SPECIFIC POPULATIONS Hepatic Impairment: Monitor for hypotension. (8.6, 12.3) SEE 17 FOR PATIENT COUNSELING INFORMATION. REVISED: 4/2022 FULL PRESCRIBING INFORMATION: CONTENTS* 1 קרא את המסמך השלם